- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.12. | NYRADA INC.: Change of Director's Interest Notice - ID | - | ASX | ||
| 18.12. | NYRADA INC.: Upcoming Expiry of Unlisted Options | - | ASX | ||
| 09.12. | NYRADA INC.: Change of Director's Interest Notice - JM | - | ASX | ||
| 09.12. | NYRADA INC.: Change of Director's Interest Notice - MF | - | ASX | ||
| 09.12. | NYRADA INC.: Change of Director's Interest Notice - RW | - | ASX | ||
| 09.12. | NYRADA INC.: Change of Director's Interest Notice - CC | - | ASX | ||
| 09.12. | NYRADA INC.: Cleansing Statement | - | ASX | ||
| 09.12. | NYRADA INC.: Application for quotation of securities - NYR | - | ASX | ||
| NYRADA INC Aktie jetzt für 0€ handeln | |||||
| 05.12. | NYRADA INC.: Change of Director's Interest Notice - JM | - | ASX | ||
| 05.12. | NYRADA INC.: Change of Director's Interest Notice - RW | - | ASX | ||
| 05.12. | NYRADA INC.: Change of Director's Interest Notice - MF | - | ASX | ||
| 05.12. | NYRADA INC.: Cleansing Statement | - | ASX | ||
| 05.12. | NYRADA INC.: Application for quotation of securities - NYR | - | ASX | ||
| 25.11. | NYRADA INC.: Investor Presentation | - | ASX | ||
| 24.11. | NYRADA INC.: Capital Structure | - | ASX | ||
| 24.11. | NYRADA INC.: Cleansing Statement | - | ASX | ||
| 24.11. | NYRADA INC.: Application for quotation of securities - NYR | - | ASX | ||
| 23.11. | NYRADA INC.: Becoming a substantial holder - Matt Corp WA PL | - | ASX | ||
| 18.11. | NYRADA INC.: Nyrada Phase IIa Clinical Trial Update | - | ASX | ||
| 13.11. | NYRADA INC.: Cleansing Statement | - | ASX |
1 2 3 4 5 Weiter >>
84 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 302,67 | +12,54 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor | The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential tremor Praxis remains on track to submit ulixacaltamide NDA... ► Artikel lesen | |
| QIAGEN | 38,755 | -0,93 % | QIAGEN N.V.: QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million | Return of approximately $500 million maximum approved by shareholders set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase combines a... ► Artikel lesen | |
| BIONTECH | 80,95 | +1,38 % | Revolutionäre Fortschritte: BioTech-Ideen für 2026! Bayer, Novo Nordisk, BioNxt, Vidac, BioNTech und Evotec! | Trotz eines schwierigen Umfelds 2025 bleibt der Biotech-Sektor fundamental attraktiv, da der medizinische Fortschritt nicht zum Stillstand kommt. Der rasante Einsatz von Künstlicher Intelligenz und... ► Artikel lesen | |
| EVOTEC | 5,436 | +4,02 % | EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Evotec SE
Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,115 | -3,06 % | Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? | ||
| PALISADE BIO | 2,450 | +13,95 % | Piper Sandler initiates Palisade Bio stock with Overweight rating on IBD drug | ||
| AVIDITY BIOSCIENCES | 72,15 | +0,01 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 25,170 | -4,51 % | Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy | - In the CIRRUS-HCM trial, including interim safety results from Part D, EDG-7500 was generally well tolerated; no clinically meaningful reductions in LVEF or LVEF - - On track to deliver... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 76,85 | -0,63 % | Apogee Therapeutics: Noch ein sharedealsPlus-Verdoppler! | Im Juli hatten wir mit der Aktie von Apogee Therapeutics einen Verdopplungskandidaten identifiziert. Jetzt, keine fünf Monate später, konnte die Aktie tatsächlich mehr als +100% zulegen. Ein weiterer... ► Artikel lesen | |
| NUVATION BIO | 9,110 | -3,14 % | Nuvation Bio to Participate in Upcoming Investor Conferences | Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief... ► Artikel lesen | |
| VERA THERAPEUTICS | 52,18 | -2,61 % | Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy | Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46%... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,470 | -1,05 % | JPMorgan Raises Cogent Biosciences (COGT) PT to $67 on Sector Model Update | ||
| MINERALYS THERAPEUTICS | 36,860 | -0,75 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| JANUX THERAPEUTICS | 13,860 | -2,74 % | Why Wall Street Sees Big Potential in Janux Therapeutics, Inc. (JANX) | ||
| BEAM THERAPEUTICS | 27,460 | -1,86 % | BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy |
Das Unternehmen NYRADA INC CDIS kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NYRADA INC CDIS finden Sie auf Wallstreet Online.